Stay updated on Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma
Sign up to get notified when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.

Latest updates to the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page
- Check6 days agoChange DetectedThe study record shows new update dates (2026-02-12, 2026-02-17, 2026-08-15) and the field 'Product Manufactured in and Exported from the U.S.' has been removed.SummaryDifference0.5%

- Check13 days agoChange DetectedThe page now shows Revision: v3.4.2, replacing the previous Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedRevision: v3.4.1 appears in the page footer, replacing v3.4.0; no other changes observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedShow glossary has been added to the page. Metadata/UI strings related to QC criteria updates and versioning were updated (e.g., 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'), including capitalization tweaks for 'No FEAR Act Data'.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 updates the page version from v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedAdded a centralized Locations section with Georgia and Ohio sites. Removed the separate Georgia Locations and Ohio Locations subsections and updated the page revision to v3.3.3.SummaryDifference0.3%

Stay in the know with updates to Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma
Enter your email address, and we'll notify you when there's something new on the Ibrutinib and Nivolumab Trial in Hodgkin Lymphoma page.